Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 8/20 | 0.59 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.59 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.59 |
| ▸ | MTOR | P42345 | 1/20 | 0.58 |
| ▸ | PRKDC | P78527 | 1/20 | 0.58 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.58 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL189928 | 0.91 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBMTOR | |
| SCHEMBL189336 | 0.85 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBMTOR | |
| SCHEMBL188745 | 0.84 | PIK3CG (0.62) | PIK3CGPIK3CDPIK3CAPIK3CBMTOR | |
| SCHEMBL189384 | 0.80 | PIK3CD (0.62) | PIK3CGPIK3CDPIK3CAPIK3CBMTOR | |
| SCHEMBL4342354 | 0.79 | PIK3CG (0.64) | PIK3CGPIK3CDPIK3CAPIK3CBMTOR | |
| SCHEMBL188913 | 0.79 | PIK3CD (0.78) | PIK3CGPIK3CDPIK3CAPIK3CBMTOR | |
| SCHEMBL189380 | 0.79 | PIK3CD (0.72) | PIK3CGPIK3CDPIK3CAPIK3CBMTOR | |
| SCHEMBL2303420 | 0.79 | PIK3CD (0.75) | PIK3CGPIK3CDPIK3CAPIK3CBMTOR | |
| SCHEMBL6996405 | 0.77 | PIK3CD (0.83) | PIK3CGPIK3CDPIK3CAPIK3CBMTOR | |
| SCHEMBL188834 | 0.77 | PIK3CD (0.79) | PIK3CGPIK3CDPIK3CAPIK3CBMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2014-04-10 | — | — | US | claimed |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2012-11-29 | — | — | US | claimed |
| EP-2056829-B9 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-09-26 | — | — | EP | claimed |
| EP-2056829-B1 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-01-04 | — | — | EP | claimed |
| EP-2364974-A1 | N-(3-Phenylamino-quinoxalin-2-yl)-benzenesulfonamide derivatives as phosphatidylinositol 3-kinase inhibitors | Exelixis, Inc. (US) | 2011-09-14 | — | — | EP | claimed |
| US-20110207712-A1 | Phosphatidylinositol 3-Kinase Inhibitors And Methods Of Their Use | EXELIXIS, INC. (US) | 2011-08-25 | — | — | US | claimed |
| US-7989622-B2 | Phosphatidylinositol 3-kinase inhibitors and methods of their use | EXELIXIS, INC. (US) | 2011-08-02 | — | — | US | claimed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | claimed |
| EP-2056829-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | Exelixis, Inc. (US) | 2009-05-13 | — | — | EP | claimed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | claimed |
| US-10328069-B2 | Phosphatidylinositol 3-kinase inhibitors for the treatment of lymphoproliferative malignancies | EXELIXIS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| EP-2773353-B1 | N-(3-{[(3-{[2-CHLORO-5-(METHOXY)PHENYL]AMINO}QUINOXALIN-2-YL)AMINO]SULFONYL}PHENYL)-2-METHYLALANINAMIDE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR FOR THE TREATMENT OF LYMPHOPROLIFERATIVE MALIGNANCIES | EXELIXIS INC (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20170296529-A1 | Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Lymphoproliferative Malignancies | EXELIXIS, INC. | 2017-10-19 | — | — | US | disclosed |
| US-9011863-B2 | Combinations of kinase inhibitors for the treatment of cancer | EXELIXIS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140303172-A1 | Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Lymphoproliferative Malignancies | EXELIXIS, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-8642584-B2 | Method of using PI3K and MEK modulators | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| EP-2364974-A1 | N-(3-Phenylamino-quinoxalin-2-yl)-benzenesulfonamide derivatives as phosphatidylinositol 3-kinase inhibitors | Exelixis, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303172-A1 | Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Lymphoproliferative Malignancies | PIK3C2A, PIK3CA, PIK3C3 | PIK3CG 15/4885PIK3CD 14/4885PIK3CA 2/4885 |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | PIK3CG 5/4885PIK3CD 2/4885PIK3CA 1/4885 |
| US-20110207712-A1 | Phosphatidylinositol 3-Kinase Inhibitors And Methods Of Their Use | PIK3CA, PIK3CB, PIK3CG | PIK3CG 3/4885PIK3CD 4/4885PIK3CA 1/4885 |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | PIK3CG 5/4885PIK3CD 2/4885PIK3CA 1/4885 |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | PIK3CG 6/4885PIK3CD 2/4885PIK3CA 1/4885 |
| US-10328069-B2 | Phosphatidylinositol 3-kinase inhibitors for the treatment of lymphoproliferative malignancies | PIK3C2A, PIK3CA, PIK3C3 | PIK3CG 15/4885PIK3CD 14/4885PIK3CA 2/4885 |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | TP53, PHKG1, TNNI3K | PIK3CG 370/4885PIK3CD 339/4885PIK3CA 145/4885 |
| US-20170296529-A1 | Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Lymphoproliferative Malignancies | PIK3C2A, PIK3CA, PIK3C3 | PIK3CG 15/4885PIK3CD 14/4885PIK3CA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.